It sounds okay to me. Select the peptides, ship them, get the infected blood samples, ship and receive the, prepare docs to go to the FDA alerting them to the next stage (testing!) in case the FDA has some ‘issue’. It looks to be like Joe is going ‘by the book’ at each stage. They’ll only get one shot at this...no ‘do over’ I’m thinking. Get it right, Joe. No SNAFU please. If the peptides are going to work, they’ll work. Remember that their history of using these peptides in the clinic means that they may get a pass on part of the review process, so they may be ahead of their competition. In any case, even if they get to the finish line late...if their peptides work, I don’t much care. We’ll all be rich and humanity will dodge the covid bullet.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links